Trusted Resource for Clinical Trials, Protocols & Progress
Randomized Controlled Trials (RCTs) are considered the gold standard in clinical research. In Phase 3 clinical trials, where the primary objective is to confirm the efficacy and safety of a treatment in large patient populations, RCTs play a pivotal role in ensuring scientific rigor, minimized bias, and regulatory acceptability.
Click to read the full article.
Once a drug is approved and enters the market, Phase 4 studies begin to monitor its performance in the real world. These studies may be observational or interventional in nature, depending on the scientific question, regulatory requirements, and feasibility. Understanding the differences between these two approaches is crucial for designing effective post-marketing research and staying compliant with global regulatory expectations.
Click to read the full article.
Phase 2 clinical trials are designed to evaluate whether a new therapeutic candidate is effective in a specific patient population. Since these trials follow the safety-focused Phase 1 stage, the emphasis shifts toward efficacy assessment, dose optimization, and continued safety monitoring. Study design plays a critical role in achieving these objectives. In this tutorial, we explore the most common Phase 2 study designs and their appropriate use cases in drug development.
Click to read the full article.
In first-in-human (FIH) trials, selecting the initial dose is one of the most important and scrutinized decisions. Too high, and you risk harm to participants. Too low, and the data may be non-informative. Regulatory authorities require this decision to be grounded in scientific rationale and supported by preclinical data. This tutorial explores the most commonly used approaches to determine the starting dose: MABEL (Minimum Anticipated Biological Effect Level), NOAEL (No Observed Adverse Effect Level), and BSA (Body Surface Area) scaling.
Click to read the full article.
Statistical considerations are the backbone of any well-designed Phase 3 clinical trial. These trials are the final stage before regulatory approval, so every aspect of the study must be quantitatively justified, especially when it comes to sample size, data variability, and the power to detect treatment differences.
Click to read the full article.
Comparative Effectiveness Research (CER) refers to the direct comparison of different treatment options to evaluate which works best for specific populations or under real-world conditions. In Phase 4 clinical trials, CER helps healthcare providers, payers, and policymakers determine the most effective and cost-efficient therapies based on real-world evidence (RWE).
Click to read the full article.
Randomized controlled trials (RCTs) are often considered the gold standard in clinical research due to their ability to minimize bias and provide high-quality evidence. In Phase 2 clinical trials, where the goal is to evaluate efficacy and optimize dosing, RCTs offer a powerful method to compare a new treatment against a control (placebo or standard of care). However, RCTs also come with practical and ethical challenges. In this tutorial, we examine the advantages and disadvantages of using randomized controlled designs in Phase 2 trials and explore when this approach is most appropriate.
Click to read the full article.
In Phase 1 clinical trials, dose escalation is a critical step in determining the maximum tolerated dose (MTD) or identifying a biologically effective dose. The design you choose directly influences patient safety, study duration, statistical rigor, and regulatory acceptance. This tutorial breaks down the most commonly used escalation methods: 3+3 design, Bayesian Optimal Interval (BOIN), modified Toxicity Probability Interval (mTPI), and Continual Reassessment Method (CRM).
Click to read the full article.
Endpoints are the measurable outcomes that determine whether a clinical trial’s objectives are achieved. In Phase 3 trials, endpoint selection is one of the most critical decisions, as it directly affects the trial’s design, statistical power, regulatory approval, and clinical relevance.
Click to read the full article.
As clinical development becomes more resource-intensive, there is a growing need for flexible and efficient trial methodologies. Adaptive designs in Phase 2 clinical trials offer the ability to make pre-specified modifications to a trial based on interim data, without undermining the study’s validity or integrity. These designs allow sponsors to optimize sample sizes, refine dose levels, drop ineffective arms, or even combine Phase 2 and 3 studies into a seamless trial. This tutorial explores the principles of adaptive designs, the value of interim analyses, and practical applications of seamless transitions in Phase 2 trials.
Click to read the full article.
